John Anthony Thompson

John Anthony Thompson's AcademicInfluence.com Rankings

Philosophy

#9521

World Rank

#13096

Historical Rank

Logic

#6495

World Rank

#8017

Historical Rank

philosophy Degrees

Download Badge

Philosophy

John Anthony Thompson's Degrees

Doctorate Medicine Harvard University

Why Is John Anthony Thompson Influential?

(Suggest an Edit or Addition)

(See a Problem?)

John Anthony Thompson's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. (2001) (2651)
Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. (2001) (2315)
Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma (2009) (2096)
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. (2018) (2082)
Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group (2017) (1274)
Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients (1999) (1216)
PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma. (2016) (976)
Phase 3 trial of everolimus for metastatic renal cell carcinoma (2010) (968)
Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance (2019) (895)
Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. (2008) (893)
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline Summary. (2018) (827)
Treatment of metastatic melanoma: an overview. (2009) (534)
A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Comparing the Tolerability and Efficacy of Ipilimumab Administered with or without Prophylactic Budesonide in Patients with Unresectable Stage III or IV Melanoma (2009) (531)
A new American Joint Committee on Cancer staging system for cutaneous melanoma (2000) (428)
An Evidence‐based Staging System for Cutaneous Melanoma 1 (2004) (420)
Management of Immunotherapy-Related Toxicities, Version 1.2019. (2019) (363)
Melanocyte Destruction after Antigen-Specific Immunotherapy of Melanoma (2000) (335)
Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer. (2004) (322)
Peroxynitrite‐Induced Cytotoxicity in PC12 Cells: Evidence for an Apoptotic Mechanism Differentially Modulated by Neurotrophic Factors (1995) (301)
Merkel cell carcinoma: Current US incidence and projected increases based on changing demographics (2017) (296)
Cutaneous Melanoma, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. (2019) (289)
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update (2021) (280)
Randomized phase II trial of sunitinib on an intermittent versus continuous dosing schedule as first-line therapy for advanced renal cell carcinoma. (2012) (263)
Guidelines of care for the management of primary cutaneous melanoma. (2019) (232)
Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody. (2004) (224)
NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020. (2020) (217)
Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: overall results of a randomized trial of the Southwest Oncology Group. (2002) (210)
Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: final results of a randomised phase III study (EORTC 18032). (2011) (210)
Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: impact of HLA class I antigen expression on outcome. (2002) (202)
Vaccination of Metastatic Renal Cancer Patients with MVA-5T4: A Randomized, Double-Blind, Placebo-Controlled Phase III Study (2010) (191)
Fractionation of grape seed extract and identification of gallic acid as one of the major active constituents causing growth inhibition and apoptotic death of DU145 human prostate carcinoma cells. (2006) (190)
Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial. (2017) (190)
Durable benefit and the potential for long-term survival with immunotherapy in advanced melanoma. (2014) (182)
Phase I study of recombinant interleukin-21 in patients with metastatic melanoma and renal cell carcinoma. (2008) (180)
The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma (2013) (174)
Transferred melanoma-specific CD8+ T cells persist, mediate tumor regression, and acquire central memory phenotype (2012) (162)
Melanoma, version 2.2016 clinical practice guidelines in oncology (2016) (161)
A phase II study of depsipeptide in refractory metastatic renal cell cancer. (2006) (147)
Interferon-induced fatigue in patients with melanoma: a pilot study of exercise and methylphenidate. (2002) (143)
New TNM melanoma staging system: linking biology and natural history to clinical outcomes. (2003) (128)
New NCCN Guidelines: Recognition and Management of Immunotherapy-Related Toxicity. (2018) (125)
Conjugate-Based Targeting of Recombinant Adeno-Associated Virus Type 2 Vectors by Using Avidin-Linked Ligands (2002) (125)
Mitochondrial targets of oxidative stress during renal ischemia/reperfusion. (2003) (120)
New therapeutic perspectives to manage refractory immune checkpoint-related toxicities. (2019) (118)
A First-in-Human Phase I Study of Subcutaneous Outpatient Recombinant Human IL15 (rhIL15) in Adults with Advanced Solid Tumors (2017) (116)
Melanoma, Version 2.2013 Featured Updates to the NCCN Guidelines (2013) (115)
Intralesional targeted alpha therapy for metastatic melanoma (2005) (108)
Fludarabine Modulates Immune Response and Extends In Vivo Survival of Adoptively Transferred CD8 T Cells in Patients with Metastatic Melanoma (2009) (107)
Phase II Study of Direct Intralesional Gene Transfer of Allovectin-7, an HLA-B7/β2-Microglobulin DNA-Liposome Complex, in Patients with Metastatic Melanoma (2001) (98)
Effect of recombinant human erythropoietin combined with granulocyte/ macrophage colony-stimulating factor in the treatment of patients with myelodysplastic syndrome (2000) (97)
Age-Specific Incidence of Melanoma in the United States. (2019) (92)
Fibroblast Growth Factor-1 Induces Heme Oxygenase-1 via Nuclear Factor Erythroid 2-related Factor 2 (Nrf2) in Spinal Cord Astrocytes (2005) (91)
Melanoma, Version 2.2016, NCCN Clinical Practice Guidelines in Oncology. (2016) (89)
A phase I study of the investigational NEDD8-activating enzyme inhibitor pevonedistat (TAK-924/MLN4924) in patients with metastatic melanoma (2016) (89)
Interim analysis of toxicity and response in phase 1 trial of systemic targeted alpha therapy for metastatic melanoma (2007) (89)
Refractory Colitis Following Anti-CTLA4 Antibody Therapy: Analysis of Mucosal FOXP3+ T Cells (2010) (87)
Southwest Oncology Group S0008: a phase III trial of high-dose interferon Alfa-2b versus cisplatin, vinblastine, and dacarbazine, plus interleukin-2 and interferon in patients with high-risk melanoma--an intergroup study of cancer and leukemia Group B, Children's Oncology Group, Eastern Cooperative (2014) (86)
MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected, MAGE-A3-positive, stage III melanoma (DERMA): a double-blind, randomised, placebo-controlled, phase 3 trial. (2018) (85)
Inflammatory enteric neuropathy with severe constipation after ipilimumab treatment for melanoma: a case report. (2009) (85)
T-Cell Therapy Using Interleukin-21-Primed Cytotoxic T-Cell Lymphocytes Combined With Cytotoxic T-Cell Lymphocyte Antigen-4 Blockade Results in Long-Term Cell Persistence and Durable Tumor Regression. (2016) (84)
Phase I dose-escalation study of SGN-75 in patients with CD70-positive relapsed/refractory non-Hodgkin lymphoma or metastatic renal cell carcinoma (2014) (83)
A Phase II Trial of Imatinib Mesylate in Merkel Cell Carcinoma (Neuroendocrine Carcinoma of the Skin): A Southwest Oncology Group Study (S0331) (2010) (81)
Randomized trial of an allogeneic melanoma lysate vaccine with low-dose interferon Alfa-2b compared with high-dose interferon Alfa-2b for Resected stage III cutaneous melanoma. (2007) (80)
Fractionation of high molecular weight tannins in grape seed extract and identification of procyanidin B2-3,3'-di-O-gallate as a major active constituent causing growth inhibition and apoptotic death of DU145 human prostate carcinoma cells. (2007) (80)
NCCN Guidelines® Insights: Melanoma: Cutaneous, Version 2.2021. (2021) (79)
NCCN Guidelines® insights: Melanoma, version 3.2016: Featured updates to the NCCN Guidelines (2016) (79)
NCCN MELANOMA PRACTICE GUIDELINES (1998) (78)
A phase I trial of CD3/CD28-activated T cells (Xcellerated T cells) and interleukin-2 in patients with metastatic renal cell carcinoma. (2003) (75)
Tumor-infiltrating BRAFV600E-specific CD4+ T cells correlated with complete clinical response in melanoma (2018) (73)
Rechallenge patients with immune checkpoint inhibitors following severe immune-related adverse events: review of the literature and suggested prophylactic strategy (2020) (72)
Preexisting Autoimmune Disease: Implications for Immune Checkpoint Inhibitor Therapy in Solid Tumors. (2019) (72)
Melanoma, version 4.2014. (2014) (71)
Phase I Study of Veliparib (ABT-888) Combined with Cisplatin and Vinorelbine in Advanced Triple-Negative Breast Cancer and/or BRCA Mutation–Associated Breast Cancer (2016) (70)
Randomized dose-escalation study evaluating peginterferon alfa-2a in patients with metastatic malignant melanoma. (2006) (66)
Combined IL-21–primed polyclonal CTL plus CTLA4 blockade controls refractory metastatic melanoma in a patient (2016) (65)
Serial Monitoring of Circulating Tumor Cells Predicts Outcome of Induction Biochemotherapy plus Maintenance Biotherapy for Metastatic Melanoma (2010) (65)
Melanoma, version 2.2013: featured updates to the NCCN guidelines. (2013) (64)
Allogeneic Hematopoietic Cell Transplantation for Metastatic Renal Cell Carcinoma after Nonmyeloablative Conditioning (2004) (64)
Fibroblast Growth Factor Receptor-1 Signaling Induces Osteopontin Expression and Vascular Smooth Muscle Cell–Dependent Adventitial Fibroblast Migration In Vitro (2002) (57)
An update on the Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma: version 2.0 (2018) (55)
Mechanistic basis for inflammation and tumor promotion in lungs of 2,6-di-tert-butyl-4-methylphenol-treated mice: electrophilic metabolites alkylate and inactivate antioxidant enzymes. (2007) (53)
The HIV-1 TAT Protein Induces the Expression and Extracellular Appearance of Acidic Fibroblast Growth Factor (*) (1995) (53)
C19orf48 Encodes a Minor Histocompatibility Antigen Recognized by CD8+ Cytotoxic T Cells from Renal Cell Carcinoma Patients (2008) (52)
Effi cacy of everolimus in advanced renal cell carcinoma : a double-blind , randomised , placebo-controlled phase III trial (2008) (52)
Management of Immunotherapy-Related Toxicities, Version 1.2022, NCCN Clinical Practice Guidelines in Oncology. (2022) (51)
Biology and systematics of Greya Busck and Tetragma (1992) (51)
Ipilimumab administration for advanced melanoma in patients with pre-existing Hepatitis B or C infection: a multicenter, retrospective case series (2014) (50)
Pembrolizumab (pembro) plus ipilimumab (ipi) for advanced melanoma: Results of the KEYNOTE-029 expansion cohort. (2016) (49)
Phase I Trial of ALT-801, an Interleukin-2/T-Cell Receptor Fusion Protein Targeting p53 (aa264–272)/HLA-A*0201 Complex, in Patients with Advanced Malignancies (2011) (49)
Phase II Trial of Recombinant Human Interleukin‐4 in Patients with Disseminated Malignant Melanoma: A Southwest Oncology Group Study (1998) (48)
Phase II trial of branched peginterferon-α 2a (40 kDa) for patients with advanced renal cell carcinoma (2002) (47)
Prognostic Gene Expression Profiling in Cutaneous Melanoma: Identifying the Knowledge Gaps and Assessing the Clinical Benefit. (2020) (45)
NCCN Guidelines Insights: Melanoma, Version 3.2016. (2016) (45)
Safety and efficacy of PF-3512676 for the treatment of stage IV renal cell carcinoma: an open-label, multicenter phase I/II study. (2009) (44)
Management of Immune-Related Adverse Events in Patients Treated With Chimeric Antigen Receptor T-Cell Therapy: ASCO Guideline (2021) (44)
Recombinant interleukin-21 plus sorafenib for metastatic renal cell carcinoma: a phase 1/2 study (2014) (43)
Interferon in the treatment of hairy cell leukemia (1987) (43)
Differential expression in Escherichia coli of the α and β forms of heparin-binding acidic fibroblast growth factor-1: potential role of RNA secondary structure (1991) (42)
Fibroblast growth factor mediates hypoxia-induced endothelin-- a receptor expression in lung artery smooth muscle cells. (2003) (42)
Systemic therapy of metastatic melanoma: on the road to cure. (2015) (42)
Effects of venous needle turbulence during ex vivo hemodialysis on endothelial morphology and nitric oxide formation. (2007) (41)
Phase II multicenter trial of maintenance biotherapy after induction concurrent Biochemotherapy for patients with metastatic melanoma. (2009) (41)
Pembrolizumab Plus Pegylated Interferon alfa-2b or Ipilimumab for Advanced Melanoma or Renal Cell Carcinoma: Dose-Finding Results from the Phase Ib KEYNOTE-029 Study (2018) (40)
The revised American Joint Committee on Cancer staging system for melanoma. (2002) (38)
Phase 1 study of ixazomib, an investigational proteasome inhibitor, in advanced non-hematologic malignancies (2015) (35)
Melanoma. Clinical practice guidelines in oncology. (2004) (34)
Immunochemical and proteomic analysis of covalent adducts formed by quinone methide tumor promoters in mouse lung epithelial cell lines. (2005) (34)
Lung toxicity and tumor promotion by hydroxylated derivatives of 2,6-di-tert-butyl-4-methylphenol (BHT) and 2-tert-butyl-4-methyl-6-iso-propylphenol: correlation with quinone methide reactivity. (2002) (32)
Safety and efficacy of ipilimumab with or without prophylactic budesonide in treatment-naive and previously treated patients with advanced melanoma (2008) (32)
Pembrolizumab (MK-3475) plus low-dose ipilimumab (IPI) in patients (pts) with advanced melanoma (MEL) or renal cell carcinoma (RCC): Data from the KEYNOTE-029 phase 1 study. (2015) (32)
Effects of ethanol ingestion and dietary fat levels on mitochondrial lipids in male and female rats (1978) (31)
Chemoprevention agents for melanoma: A path forward into phase 3 clinical trials (2018) (31)
Sodium nitrite protects against kidney injury induced by brain death and improves post-transplant (2012) (31)
Induction of complete remission of advanced stage mycosis fungoides by allogeneic hematopoietic stem cell transplantation. (2002) (30)
A phase 1 trial of SGN‐CD70A in patients with CD70‐positive, metastatic renal cell carcinoma (2019) (30)
Inhibition of glutathione S-transferase P1-1 in mouse lung epithelial cells by the tumor promoter 2,6-di-tert-butyl-4-methylene-2,5-cyclohexadienone (BHT-quinone methide): protein adducts investigated by electrospray mass spectrometry. (2004) (28)
First in human (FIH) study of an OX40 agonist monoclonal antibody (mAb) PF-04518600 (PF-8600) in adult patients (pts) with select advanced solid tumors: Preliminary safety and pharmacokinetic (PK)/pharmacodynamic results. (2016) (28)
Procyanidin B2 3,3″-di-O-gallate, a Biologically Active Constituent of Grape Seed Extract, Induces Apoptosis in Human Prostate Cancer Cells Via Targeting NF-κB, Stat3, and AP1 Transcription Factors (2014) (28)
A phase 2, single‐arm study of ramucirumab in patients with metastatic renal cell carcinoma with disease progression on or intolerance to tyrosine kinase inhibitor therapy (2014) (28)
Analysis of Coronavirus Temperature-Sensitive Mutants Reveals an Interplay between the Macrodomain and Papain-Like Protease Impacting Replication and Pathogenesis (2019) (27)
The absolute bioavailability of oral vinorelbine in patients with solid tumors (2005) (27)
Fatal enteric plexus neuropathy after one dose of ipilimumab plus nivolumab: a case report (2018) (26)
Neoantigen-specific CD4+ T cells in human melanoma have diverse differentiation states and correlate with CD8+ T cell, macrophage, and B cell function. (2022) (26)
Ipilimumab in Treatment-naive and Previously Treated Patients with Metastatic Melanoma: Retrospective Analysis of Efficacy and Safety Data from a Phase II Trial (2012) (26)
Fast neutron radiotherapy for primary mucosal melanomas of the head and neck (2014) (25)
Ligand activation of alternatively spliced fibroblast growth factor receptor-1 modulates pancreatic adenocarcinoma cell malignancy (2002) (25)
Phase I studies of anti-ENPP3 antibody drug conjugates (ADCs) in advanced refractory renal cell carcinomas (RRCC). (2015) (25)
Systemic therapy for metastatic melanoma in 2012: dawn of a new era. (2012) (25)
Influence of Gallate Esterification on the Activity of Procyanidin B2 in Androgen-Dependent Human Prostate Carcinoma LNCaP Cells (2010) (23)
Ipilimumab administration in patients with advanced melanoma and hepatitis B and C. (2013) (23)
Temsirolimus in patients with advanced renal cell carcinoma: an overview (2009) (23)
Efficacy and safety of vedolizumab and infliximab treatment for immune-mediated diarrhea and colitis in patients with cancer: a two-center observational study (2021) (23)
Immune activation in advanced cancer patients treated with recombinant IL-21: multianalyte profiling of serum proteins (2009) (23)
A Single Direct Intratumoral Injection of TTI-621 (SIRPαFc) Induces Antitumor Activity in Patients with Relapsed/Refractory Mycosis Fungoides and Sézary Syndrome: Preliminary Findings Employing an Immune Checkpoint Inhibitor Blocking the CD47 Do Not Eat Signal (2017) (22)
Phase III trial of high-dose interferon alpha-2b versus cisplatin, vinblastine, DTIC plus IL-2 and interferon in patients with high-risk melanoma (SWOG S0008): An intergroup study of CALGB, COG, ECOG, and SWOG. (2012) (22)
Phase I Trials of Anti-ENPP3 Antibody–Drug Conjugates in Advanced Refractory Renal Cell Carcinomas (2018) (22)
A Phase I, Open-Label, Dose-Escalation Study of the OX40 Agonist Ivuxolimab in Patients with Locally Advanced or Metastatic Cancers (2021) (22)
Fecal calprotectin concentration to assess endoscopic and histologic remission in patients with cancer with immune-mediated diarrhea and colitis (2021) (22)
NCCN Guidelines Insights: Uveal Melanoma, Version 1.2019. (2020) (21)
Alternatively spliced FGFR-1 isoforms differentially modulate endothelial cell activation of c-YES. (2006) (21)
Development of modified vaccinia Ankara-5T4 as specific immunotherapy for advanced human cancer (2008) (20)
Subcutaneous recombinant gamma interferon in cancer patients: toxicity, pharmacokinetics, and immunomodulatory effects (2004) (20)
Intralesional TTI-621, a novel biologic targeting the innate immune checkpoint CD47, in patients with relapsed or refractory mycosis fungoides or Sézary syndrome: a multicentre, phase 1 study. (2021) (20)
22LBA Activity of PD-1 blockade with pembrolizumab as first systemic therapy in patients with advanced Merkel cell carcinoma (2015) (19)
Total body irradiation, etoposide, cyclophosphamide, and autologous peripheral blood stem-cell transplantation followed by randomization to therapy with interleukin-2 versus observation for patients with non-Hodgkin lymphoma: results of a phase 3 randomized trial by the Southwest Oncology Group (SWO (2006) (19)
A phase 2 randomised study of ramucirumab (IMC-1121B) with or without dacarbazine in patients with metastatic melanoma. (2014) (18)
Very low dose alpha-2b interferon for the treatment of hairy cell leukemia [see comments] (1989) (18)
Responses of tumorigenic and non-tumorigenic mouse lung epithelial cell lines to electrophilic metabolites of the tumor promoter butylated hydroxytoluene. (2003) (18)
Protein damage from electrophiles and oxidants in lungs of mice chronically exposed to the tumor promoter butylated hydroxytoluene. (2011) (17)
Long-term Follow-up of Standard-Dose Pembrolizumab Plus Reduced-Dose Ipilimumab in Patients with Advanced Melanoma: KEYNOTE-029 Part 1B (2020) (17)
Phase 2 trial of combination thalidomide plus temozolomide in patients with metastatic malignant melanoma: Southwest Oncology Group S0508 (2010) (17)
Phase Ib trial of a targeted TLR9 CpG immunomodulator (CPG 7909) in advanced renal cell carcinoma (RCC) (2004) (16)
Melanoma: Clinical practice guidelines in oncology™ (2006) (16)
Pembrolizumab plus ipilimumab for advanced melanoma : results of the keynote-029 expansion cohort (2016) (16)
Peroxynitrite modulates acidic fibroblast growth factor (FGF-1) activity. (2003) (16)
The relationship of pharmacodynamics (PD) and pharmacokinetics (PK) to clinical outcomes in a phase I study of OX40 agonistic monoclonal antibody (mAb) PF-04518600 (PF-8600). (2017) (15)
Association of Chronic Immune-Mediated Diarrhea and Colitis With Favorable Cancer Response. (2020) (15)
Phase I: Veliparib with cisplatin (CP) and vinorelbine (VNR) in advanced triple-negative breast cancer (TNBC) and/or BRCA mutation-associated breast cancer. (2014) (15)
Immune Checkpoint Inhibitor Use in Solid Organ Transplant Recipients: A Systematic Review. (2022) (14)
A first-in-human (FIH) study of PF-04518600 (PF-8600) OX40 agonist in adult patients (pts) with select advanced malignancies (2016) (14)
Cutaneous Melanoma , Version 2 . 2019 (2019) (13)
Melanoma and other skin tumors (2012) (13)
A Randomized Phase II Study of AGS-16C3F Versus Axitinib in Previously Treated Patients with Metastatic Renal Cell Carcinoma. (2020) (13)
7108 Phase II study of IMC-1121B in patients with metastatic renal cell carcinoma (mRCC) following failure of VEGFR-2 tyrosine kinase inhibitor (TKI) therapy: interim results (IMCL CP12–0605/NCT00515697) (2009) (12)
Evaluation of interferon alpha‐2B and thalidomide in patients with disseminated malignant melanoma, phase 2, SWOG 0026 (2007) (12)
First-in-human, phase I dose-escalation study of investigational drug MLN9708, a second-generation proteasome inhibitor, in advanced nonhematologic malignancies. (2010) (12)
New route for metastatic spread of melanoma? (1993) (11)
31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two (2016) (11)
Safety and efficacy of combination nivolumab plus ipilimumab in patients with advanced melanoma: results from a North American expanded access program (CheckMate 218) (2020) (11)
A phase II randomized study of ramucirumab (IMC-1121B) with or without dacarbazine (DTIC) in patients (pts) with metastatic melanoma (MM). (2010) (11)
Phase I study of single agent NIZ985, a recombinant heterodimeric IL-15 agonist, in adult patients with metastatic or unresectable solid tumors (2021) (11)
KEYNOTE-029: Efficacy and safety of pembrolizumab (pembro) plus ipilimumab (ipi) for advanced melanoma. (2017) (10)
Outcomes in Patients With Metastatic Renal Cell Carcinoma Who Develop Everolimus-Related Hyperglycemia and Hypercholesterolemia: Combined Subgroup Analyses of the RECORD-1 and REACT Trials (2016) (10)
Alternatively spliced FGFR-1 isoform signaling differentially modulates endothelial cell responses to peroxynitrite. (2003) (10)
The natural history of melanoma and factors predicting outcome (2003) (10)
Carbonyl reductase inactivation may contribute to mouse lung tumor promotion by electrophilic metabolites of butylated hydroxytoluene: protein alkylation in vivo and in vitro. (2008) (10)
31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one (2016) (10)
Major Changes in Systemic Therapy for Advanced Melanoma. (2016) (9)
Melanoma: immune checkpoint blockade story gets better (2014) (9)
Phase I dose escalation study of recombinant interleukin-21 (rIL-21; BMS-982470) in combination with nivolumab (anti-PD-1; BMS-936558; ONO-4538) in patients (pts) with advanced or metastatic solid tumors. (2013) (9)
Intralesional Administration of the CD47 Antagonist TTI-621 (SIRPαFc) Induces Responses in Both Injected and Non-Injected Lesions in Patients with Relapsed/Refractory Mycosis Fungoides and Sézary Syndrome: Interim Results of a Multicenter Phase I Trial (2018) (9)
Adjuvant Vaccine Immunotherapy of Resected, Clinically Node-Negative Melanoma: Long-term Outcome and Impact of HLA Class I Antigen Expression on Overall Survival (2014) (8)
Allogeneic hematopoietic cell transplantation for renal cell carcinoma: ten years after (2011) (8)
P860 Results from a combination of OX40 (PF-04518600) and 4–1BB (utomilumab) agonistic antibodies in melanoma and non-small cell lung cancer in a phase 1 dose expansion cohort (2020) (8)
A phase II open-label trial of apomine (SR-45023A) in patients with refractory melanoma (2006) (8)
Phase II trial of combination thalidomide (thal) plus temozolomide (TMZ [TT]), in patients with metastatic malignant melanoma (MMM): Southwest Oncology Group S0508 (2008) (8)
The Effect of Supplementary Omegaven® on the Clinical Outcome of Patients With Advanced Esophagogastric Adenocarcinoma Receiving Palliative Epirubicin, Oxaliplatin, and Capecitabine Chemotherapy: A Phase II clinical trial (2019) (8)
Phase II Study of Direct Intralesional Gene Transfer of Allovectin-7 , an HLA-B 7 / 2-Microglobulin DNA-Liposome Complex , in Patients with Metastatic Melanoma 1 (2001) (8)
ILX651 administered daily for five days every 3 weeks (qdx5dq3w) in patients (pts) with inoperable locally advanced or metastatic melanoma: Phase II experience (2005) (8)
Effect of prior treatment status on the efficacy and safety of ipilimumab monotherapy in treatment-naive and previously treated patients with advanced melanoma (2008) (8)
Overall survival (OS) analysis from an expanded access program (EAP) of nivolumab (NIVO) in combination with ipilimumab (IPI) in patients with advanced melanoma (MEL). (2017) (7)
Intralesional Injection of the CD47-blocking immune checkpoint inhibitor TTI-621 (SIRPaFc) induces antitumor activity in patients with relapsed/refractory mycosis fungoides and Sézary syndrome: Interim results of a multicenter Phase 1 trial (2018) (7)
The role of cytochrome P450 BM3 phenylalanine-87 and threonine-268 in binding organic hydroperoxides. (2016) (7)
Clinicopathologic Features, Treatment Response, and Outcomes of Immune Checkpoint Inhibitor–Related Esophagitis (2021) (7)
Myeloid derived suppressor cells are reduced and T regulatory cells stabilised in patients with advanced pancreatic cancer treated with gemcitabine and intravenous omega 3 (2020) (7)
Preliminary tolerability and anti-tumor activity of intravenous recombinant human Interleukin-21 (IL-21) in patients with metastatic melanoma and metastatic renal cell carcinoma (2005) (7)
Ten years of progress in melanoma. (2012) (7)
Triphendiol (NV-196), development of a novel therapy for pancreatic cancer (2011) (7)
Glomerular targeting of acidic fibroblast growth factor-1 in renal transplanted rats1 (2002) (6)
Antibacterial properties of an iron-based hemostatic agent in vitro and in a rat wound model. (2009) (6)
A Phase I Trial of CD 3 / CD 28-activated T Cells ( Xcellerated T Cells ) and Interleukin-2 in Patients with Metastatic Renal Cell Carcinoma 1 (2003) (6)
Recombinant IL-21 (rIL-21) in combination with sorafenib: Interim results from a phase 1/2 study in patients with metastatic renal cell cancer (mRCC) (2008) (6)
Combining immune checkpoint inhibition plus tyrosine kinase inhibition as first and subsequent treatments for metastatic renal cell carcinoma (2022) (6)
Pembrolizumab (pembro) plus ipilimumab (ipi) or pegylated interferon alfa-2b (PEG-IFN) for advanced melanoma or renal cell carcinoma (RCC). (2016) (6)
First-in-human study of an OX40 (ivuxolimab) and 4-1BB (utomilumab) agonistic antibody combination in patients with advanced solid tumors (2022) (5)
Everolimus with bevacizumab versus interferon alfa-2a plus bevacizumab as first-line therapy in patients with metastatic clear cell renal cell carcinoma. (2010) (5)
ADAM trial: A multicenter, randomized, double-blinded, placebo-controlled, phase 3 trial of adjuvant avelumab (anti-PD-L1 antibody) in merkel cell carcinoma patients with clinically detected lymph node metastases; NCT03271372. (2018) (5)
Untangling the Multidisciplinary Care Web: Streamlining Care Through an Immune-Related Adverse Events (IRAE) Tumor Board (2020) (5)
Pembrolizumab (pembro) plus low-dose ipilimumab (ipi) for patients (pts) with advanced renal cell carcinoma (RCC): Phase 1 KEYNOTE-029 study. (2017) (5)
Recombinant alpha2 interferon for the treatment of hairy cell leukemia (1985) (5)
TFEB Amplification Renal Cell Carcinoma Detected by Chromosome Genomic Array Testing: A Case Report for Diagnosis of a Novel Entity (2017) (5)
Should unknown primary melanomas be excluded from adjuvant therapy trials? Insights from SWOG S0008. (2010) (5)
Metastatic renal cell carcinoma: current standards of care. (2009) (4)
523 Preliminary clinical experience with XmAb20717, a PD-1 x CTLA-4 bispecific antibody, in patients with advanced solid tumors (2021) (4)
PD-1 Blockade in Melanoma: A Promising Start, but a Long Way to Go. (2016) (4)
Mechanism of action of everolimus in renal cell carcinoma (2009) (4)
Panniculitis in a patient with pathologic complete response to talimogene laherparepvec treatment for recurrent, in‐transit melanoma (2018) (4)
Protocol #0207-544: a phase study to evaluate the safety and pharmacokinetics of Pro-1, a liposome-encapsulated thymidine kinase gene formulation, in patients with stage IV metastatic melanoma. (2003) (4)
Immunologic adverse events from immune checkpoint therapy. (2020) (4)
Effects of chronic ethanol ingestion upon acyl-CoA: Carnitine acyltransferase in liver and heart (1974) (4)
C 19 orf 48 Encodes aMinor HistocompatibilityAntigen Recognized by CD 8 + CytotoxicTCells from Renal Cell Carcinoma Patients (2008) (3)
Recent advances in the use of antigen-specific T cells for the treatment of cancer (2006) (3)
407 Preliminary safety, pharmacokinetics/pharmacodynamics, and antitumor activity of XmAb20717, a PD-1 x CTLA-4 bispecific antibody, in patients with advanced solid tumors (2020) (3)
Abstract CT082: Phase (Ph) I/Ib study of NIZ985 with and without spartalizumab (PDR001) in patients (pts) with metastatic/unresectable solid tumors (2019) (3)
Abstract 5535: SEA-CD40 is a non-fucosylated anti-CD40 antibody with potent pharmacodynamic activity in preclinical models and patients with advanced solid tumors (2020) (3)
Tumor drug distribution and target engagement of MLN9708, an investigational proteasome inhibitor, in patients with advanced solid tumors. (2012) (3)
A phase 1 dose-escalation trial of intratumoral TTI-621, a novel immune checkpoint inhibitor targeting CD47, in subjects with relapsed or refractory percutaneously-accessible solid tumors and mycosis fungoides. (2017) (3)
A multicenter study assessing survival in patients with metastatic renal cell carcinoma receiving immune checkpoint inhibitor therapy with and without cytoreductive nephrectomy. (2022) (3)
MLN9708, an investigational proteasome inhibitor, in patients (pts) with solid tumors: Updated phase I results. (2012) (2)
Treatment options expanding for advanced melanoma. (2015) (2)
Occult primary cancer clinical practice guidelines. (2005) (2)
CITN11-02 interim trial results: subcutaneous administration of recombinant human IL-15 (rhil-15) is associated with robust expansion of peripheral blood CD56+ NK cells (2014) (2)
Complex, in Patients with Advanced Malignancies (2011) (2)
Can’t handle the itch? Refractory immunotherapy-related transient acantholytic dermatosis: prompt resolution with dupilumab (2022) (2)
Iconography : Guidelines of care for the management of primary cutaneous melanoma (2018) (2)
A phase II study of depsipeptide (Dep) in patients (pts) with metastatic renal cell cancer (RCC) (2005) (2)
Phase I dose escalation study of recombinant interleukin-21 (rIL-21, BMS-982470) in combination with ipilimumab (Ipi) in patients (pts) with advanced or metastatic melanoma (MM). (2013) (2)
719 EVEROLIMUS IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA: SUBGROUP ANALYSIS OF PATIENTS WITH A REDUCTION IN TUMOR BURDEN ENROLLED IN A RANDOMIZED, PLACEBO-CONTROLLED, PHASE II TRIAL (2011) (2)
CITN11-02 interim trial results: subcutaneous administration of recombinant human IL-15 (rhIL-15) is associated with expansion of peripheral blood CD56+ NK cells and CD8+ T cells (2015) (2)
265 POSTER Recombinant human Interleukin-21 (rIL-21), a new cytokine for immunotherapy: results of two phase 1 studies in patients with metastatic melanoma (MM) or renal cell carcinoma (RCC) (2006) (2)
Outcomes and clinical markers associated with benefit from ipilimumab (Ipi) in patients with advanced melanoma: A retrospective single-institution study. (2013) (2)
Maintenance immunosuppressive therapy with resumption of immune checkpoint inhibitor treatment to reduce recurrence of immune-mediated colitis. (2021) (2)
Clinical experience of a targeted TCR-IL2 fusion protein in combination with cisplatin (CDDP) in patients (pts) with metastatic melanoma. (2012) (2)
Safety data from an expanded access program (EAP) of nivolumab (NIVO) in combination with ipilimumab (IPI) in patients with advanced melanoma (MEL). (2016) (2)
Extended duration of anti-PD-1 therapy, using reduced frequency dosing, in patients with advanced melanoma and Merkel cell carcinoma. (2022) (2)
Surgical excision margins for localised cutaneous melanoma (2004) (2)
Ex vivo isolation of RCC-reactive CD8+ CTL clones from HLA-identical allogeneic donor T cell lines stimulated by CD80-transfected tumor cells (2007) (2)
A Phase 2 Randomized Study of Ramucirumab (IMC 1121B; RAM) with or Without Dacarbazine (DTIC) in Patients (PTS) with Metastatic Melanoma (MM) (CP12-0604/NCT00533702) (2012) (2)
A second chance for success with BRAF and MEK inhibitors in melanoma. (2017) (2)
1142PDSafety, pharmacokinetics (PK) and pharmacodynamics (PD) data from a phase I dose-escalation study of OX40 agonistic monoclonal antibody (mAb) PF-04518600 (PF-8600) in combination with utomilumab, a 4-1BB agonistic mAb (2017) (2)
1210 POSTER Phase 1 Study of MLN9708, an Investigational Proteasome Inhibitor, in Advanced Nonhematologic Malignancies- Updated Results (2011) (2)
Use of interleukin-2 after bone marrow transplantation (1995) (2)
Corrections: Heparain-Binding Growth Factor 1 Induces the Formation of Organoid Neovascular Structures In vivo (1990) (1)
Generation of lymphokine-activated killer (LAK) activity in vivo with recombinant interleukin 2 (1985) (1)
Abstract LB-136: IL-21-derived melanoma-reactive CTL combined with anti-CTLA4 persist, acquire central memory characteristics, and mediate tumor regression in patients with metastatic melanoma (2012) (1)
Relationship between biomarkers and everolimus efficacy in the phase III RECORD-1 trial of patients with metastatic renal cell carcinoma (mRCC). (2013) (1)
Clinicopathologic Features, Treatment Response, and Outcomes of Immune Checkpoint Inhibitor-Related Esophagitis. (2020) (1)
MelanomaPractice Guidelines in Oncology (2012) (1)
Prognostic F actors A nalysis o f 1 7,600 M elanoma P atients: Validation o f t he A merican J oint C ommittee o n C ancer Melanoma S taging S ystem (2001) (1)
Interferon alfa-2b/melphalan/prednisone in previously untreated patients with multiple myeloma: a phase I–II trial (2004) (1)
Identification of A Well-tolerated Outpatient Regimen of Interleukin-21 (IL-21) in Patients With Metastatic Melanoma and Renal Cell Carcinoma (RCC) (2005) (1)
Eosinophilic fasciitis as a paraneoplastic syndrome in melanoma (2021) (1)
The treatment of hairy cell leukemia with recombinant alfa interferon: a multi-institutional study (2004) (1)
Fr507 IMMUNE CHECKPOINT INHIBITOR RESUMPTION IS ASSOCIATED WITH BETTER LONG TERM OUTCOMES IN CANCER PATIENTS (2021) (1)
C19orf48 Encodes a RCC-Associated Minor H Antigen 1 C19orf48 Encodes a Minor Histocompatibility Antigen Recognized by CD8 Cytotoxic T Cells from Renal Cell Carcinoma Patients Running Title: C19orf48 Encodes a RCC-Associated Minor H Antigen Authors: (2008) (1)
Predictive lifestyle markers for efficacy of cancer immune checkpoint inhibitors: a commentary. (2021) (1)
9306 ORAL Safety and Efficacy of Ipilimumab-treated Patients With Melanoma and Brain Metastases (2011) (1)
Associating sleep problems with advanced cancer diagnosis, and immune checkpoint treatment outcomes: a pilot study (2021) (1)
Phase II trial of the CDK4/6 inhibitor abemaciclib in patients (pts) with advanced and refractory well‐differentiated gastroenteropancreatic neuroendocrine tumors (GEP NETs). (2021) (1)
204 POSTER Recombinant IL-21 in combination with sorafenib as second or third-line therapy for metastatic renal cell carcinoma (mRCC): Interim results from a Phase 2 study (2008) (1)
Efficacy and Safety of Vedolizumab and Infliximab Treatment for Immune-Mediated Diarrhea and Colitis in Cancer Patients: A Multi-Center Study (2021) (1)
AGGRESSIVE SURGICAL RESECTION COMBINED WITH LOW-DOSE RIL 2-BASED ADOPTIVE IMMUNOTHERAPY FOR TREATMENT OF METASTATIC RENAL CELL CARCINOMA (MRCC); SURGICAL BIOLOGY OF A LARGE MULTI-CENTER RANDOMIZED PLACEBO CONTROLLED PHASE II/III STUDY (1999) (1)
Academic Cancer Center Phase I Program Development (2017) (1)
Abstract CT010: Pharmacodynamic (PD) changes in tumor RNA expression and the peripheral blood T cell receptor (TCR) repertoire in a phase I study of OX40 agonistic monoclonal antibody (mAb) PF-04518600 (PF-8600) (2018) (1)
Electrocardiographic Characterization of Ramucirumab on the Corrected QT Interval in a Phase II Study of Patients With Advanced Solid Tumors (2016) (1)
An update on advanced therapies for Parkinson's disease: From gene therapy to neuromodulation (2022) (0)
Abstract CT065: KEYNOTE 029: A phase I/II randomized trial of pembrolizumab (pembro) plus 2 dose regimens of ipilimumab (ipi) for advanced melanoma (2017) (0)
Very Low Dose a-2 b Interferon for the Treatment of Hairy Cell Leukemia (2005) (0)
Agents make "preferred list" in metastatic melanoma. (2014) (0)
OTHR-08. PREDICTION OF RISK OF CENTRAL NERVOUS SYSTEM METASTASIS FOR AJCC 8TH EDITION STAGE III MELANOMA PATIENTS (2019) (0)
Characteristics, treatment, and outcome of diverticulitis after immune checkpoint inhibitor treatment in patients with malignancies. (2022) (0)
Ligand activation of alternatively spliced FGFR-1 modulates pancreatic cancer cell malignancy (2001) (0)
Abstract CT096: Clinical activity, immune and viral correlates of PD-1 blockade with pembrolizumab as first systemic therapy in patients with advanced Merkel cell carcinoma (2016) (0)
Biomarkers of Everolimus Efficacy in Patients with Metastatic Renal Cell Carcinoma (MRCC): Analysis of the Phase III Record-1 Trial (2012) (0)
PHASE 1 TRIALS OF ANTI-ENPP3 ANTIBODY DRUG CONJUGATES IN ADVANCED REFRACTORY RENAL CELL CARCINOMAS (2018) (0)
IL-2-BASED CONSOLIDATIVE IMMUNOTHERAPY AFTER AUTOLOGOUS BONE MARROW TRANSPLANTATION (1993) (0)
ARY acellular FGF-1 acts as a lens differentiat (0)
23 EFFICACY AND SAFETY OF VEDOLIZUMAB AND INFLIXIMAB TREATMENT FOR IMMUNE-MEDIATED DIARRHEA AND COLITIS IN CANCER PATIENTS: A MULTI-CENTER STUDY (2021) (0)
386 Phase I/Ib first-in-human study of HEK-NIZ985, a recombinant IL-15/IL-15Rα heterodimer, alone and in combination with spartalizumab, in adults with advanced and metastatic solid tumors (2020) (0)
Use of IL-2 and Lymphocytes Following Bone Marrow Transplantation (1992) (0)
Abstract 5648: Influence of gallate esterification on the activity of procyanidin B2 in androgen-dependent human prostate carcinoma LNCaP cells (2010) (0)
Iconographies supplémentaires de l'article : Guidelines of care for the management of primary cutaneous melanoma (2018) (0)
smooth muscle cells endothelin-A receptor expression in lung artery Fibroblast growth factor mediates hypoxia-induced (2015) (0)
697 Assessment of the tolerability, safety and efficacy of increasing doses of peginterferon alfa-2a (40KD) in a randomised study in patients with metastatic malignant melanoma (2003) (0)
NCCN Melanoma Clinical Practice Guidelines in Oncology (2012) (0)
Adoptive Cell Transfer and Lymphodepleting Chemotherapy for the Treatment of Metastatic Melanoma (2011) (0)
Su481 MAINTENANCE THERAPY REDUCES RECURRENCE OF IMMUNE-MEDIATED COLITIS AFTER RESUMPTION OF IMMUNOTHERAPY IN CANCER PATIENTS (2021) (0)
Adoptively transferred melanoma-reactive CTL primed in the presence of IL-21 and transferred with concurrent CTLA4 blockade results in enhanced CTL persistence and tumor regression (2014) (0)
Inflammatory colitis after treatment of melanoma with talimogene laherparepvec (T-VEC) (2018) (0)
A polymorphic oncofetal antigen recognized by CD8(+) CTL from two patients experiencing regression of metastatic renal cell carcinoma after allogeneic HCT. (2005) (0)
CITN11-02 phase I trial of subcutaneous recombinant human IL-15 (rhIL-15) is associated with expansion of circulating CD56+ NK cells and CD8+ T cells (2016) (0)
Phase 1b dose escalation study to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of GS-3583, a FLT3 agonist Fc fusion protein, in patients with advanced solid tumors. (2021) (0)
Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma. (2023) (0)
)NA/restriction fragment extension/ (2016) (0)
ADAM Trial: A multicenter, randomized, double-blinded, placebo-controlled, phase 3 trial of adjuvant avelumab (anti-PD-L1 antibody) in Merkel cell carcinoma patients with lymph node metastases; NCT03271372 (2022) (0)
NCCN: Continuing Education (2019) (0)
New prescribing options in metastatic melanoma (2013) (0)
Novel Cytokines for Immunotherapy of Melanoma (2012) (0)
1257TiPKEYNOTE 029: Phase 1/2 randomized study of pembrolizumab (pembro) plus 2 dose regimens of ipilimumab (ipi) for advanced melanoma (2017) (0)
Clinical outcomes of patients with metastatic renal cell carcinoma who discontinued nivolumab +/- ipilimumab therapy electively or due to toxicity. (2023) (0)
Erratum: Jeter JM, Bowles TL, Curiel‐Lewandrowski C, et al. Chemoprevention agents for melanoma: A path forward into phase 3 clinical trials. Cancer. 2019:125:18‐44. (2019) (0)
Abstract PR11: Enhanced in vivo persistence and therapeutic activity of combined transferred polyclonal melanoma-reactive CTL generated in presence of IL-21 and anti-CTLA4. (2013) (0)
Su482 FECAL CALPROTECTIN CONCENTRATION TO ASSESS ENDOSCOPIC AND HISTOLOGIC REMISSION IN PATIENTS WITH IMMUNE-MEDIATED DIARRHEA AND COLITIS (2021) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With John Anthony Thompson?

John Anthony Thompson is affiliated with the following schools:

University of Sydney
University of Oxford
Wayne State University
University of Southern California
Vanderbilt University
University of Washington
University of Alabama at Birmingham